☆ 4.5 Letter

Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission

BONE MARROW TRANSPLANTATION (2016)

Journal

BONE MARROW TRANSPLANTATION

Volume 51, Issue 4, Pages 610-611

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/bmt.2015.305

Keywords

-

Categories

Biophysics Oncology Hematology Immunology Transplantation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Biophysics

Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Xiao-jun Huang, Didier Blaise, William Arcese, Mercedes Colorado Araujo, Gerard Socie, Edouard Forcade, Fabio Ciceri, Jonathan Canaani, Sebastian Giebel, Eolia Brissot, Jaime Sanz Caballer, Ali Bazarbachi, Ibrahim Yakoub-Agha, Mohamad Mohty

Summary: This study compared the transplantation outcomes of AML patients undergoing HaploSCT in CR1 after one or two induction chemotherapy courses. The results showed that patients achieving CR1 with two induction courses had a higher relapse incidence and inferior leukemia-free survival, overall survival, and GVHD-free, relapse-free survival compared to those achieving CR1 with one induction course.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Biophysics

Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde-Dahl, Jan J. J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Peter Remenyi, Gerard Socie, Gwendolyn van Gorkom, Helene Labussiere-Wallet, Xiao-Jun Huang, Marie Therese Rubio, Jenny Byrne, Charles Craddock, Laimonas Griskevicius, Fabio Ciceri, Mohamad Mohty

Summary: This study compared the outcomes of hematopoietic stem cell transplants in acute myeloid leukemia patients in first complete remission from different donor sources. The results showed that acute graft-versus-host disease (GVHD) was more common in all non-sibling donor groups. Chronic GVHD rates were also higher in certain unrelated donor groups. However, overall survival and leukemia-free survival did not differ significantly between donor types.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Oncology

Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermudez Rodriguez, Peter Remenyi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty

Summary: Comparing outcomes of adult patients with secondary acute myeloid leukemia (sAML) and de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide, no significant difference was observed in transplantation outcomes between the two groups.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Article Hematology

Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study

Frederic Baron, Arnon Nagler, Jacques-Emmanuel Galimard, Jaime Sanz, Jurjen Versluis, Edouard Forcade, Patrice Chevallier, Anne Sirvent, Chloe Anthias, Jurgen Kuball, Sabine Furst, Alessandro Rambaldi, Jorge Sierra, Peter A. von Dem Borne, Maria Pilar Gallego Hernanz, Thomas Cluzeau, Stephen Robinson, Anna Maria Raiola, Helene Labussiere-Wallet, Jenny L. Byrne, Jean-Valere Malfuson, Annalisa Ruggeri, Mohamad Mohty, Fabio Ciceri

Summary: We investigated whether secondary versus de novo AML would be associated with poor outcomes in adult acute AML patients in first complete remission (CR1) receiving unrelated cord blood transplantation (CBT). We observed non-significantly different leukaemia-free survival (LFS) and relapse incidence (RI) in de novo versus secondary AML patients.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Biophysics

The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT

Arnon Nagler, Myriam Labopin, Nicolaus Kroeger, Thomas Schroeder, Tobias Gedde-Dahl, Matthias Eder, Georg-Nikolaus Franke, Igor Wolfgang Blau, Urpu Salmenniemi, Gerard Socie, Johannes Schetelig, Matthias Stelljes, Fabio Ciceri, Mohamad Mohty

Summary: By comparing outcomes of 1609 patients with secondary acute myeloid leukemia (sAML) undergoing allogeneic transplantation, it was found that antithymocyte globulin (ATG) treatment resulted in lower incidence of GVHD and improved overall survival and GVHD-free, relapse-free survival without increasing relapse incidence.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Biophysics

The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study

Arnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, Benedetto Bruno, Alessandro Rambaldi, Pietro Pioltelli, Giorgio La Nasa, Gerard Socie, Stephan Mielke, Marco Ruggeri, Riccardo Saccardi, Georg-Nikolaus Franke, Juergen Finke, Bipin N. Savani, Annalisa Ruggeri, Mohamad Mohty

Summary: The study showed that allo-HCT from >= 2 HLA allele MMUD in acute leukemia patients resulted in acceptable leukemia-free survival and refined GVHD-free, relapse-free survival, although HLA-DR mismatch was identified as a poor prognostic factor.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection

Letter Oncology

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

Frederic Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stoelzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Summary: A study on the association between the occurrence of GVHD and the relapse of AML in patients undergoing Haplo-HCT with PTCy-based GVHD prophylaxis found that while grade I acute GVHD was associated with better LFS, grade III-IV acute and extensive chronic GVHD were correlated with higher nonrelapse mortality and lower LFS.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Article Hematology

Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study

Joshua A. Fein, Roni Shouval, Jacques-Emmanuel Galimard, Myriam Labopin, Gerard Socie, Juergen Finke, Jan J. Cornelissen, Ram Malladi, Maija Itala-Remes, Patrice Chevallier, Kim H. Orchard, Donald Bunjes, Mahmoud Aljurf, Marie Therese Rubio, Jurjen Versluis, Mohamad Mohty, Arnon Nagler

Summary: Older age and comorbidities are factors that influence the selection of low-intensity conditioning regimens in allogeneic hematopoietic stem cell transplantation recipients. This study aimed to determine the impact of individual comorbidities and their cumulative burden on the risk of nonrelapse mortality (NRM) in patients receiving low-intensity regimens. The findings showed an association between cardiac comorbidity, psychiatric disease, and increased NRM risk.

BLOOD ADVANCES (2023)

Add to Collection

Article Urology & Nephrology

Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant

Karyne Pelletier, Gabrielle Cote, Kayla Madsen, Shiyi Chen, S. Joseph Kim, Christopher T. Chan, Jonas Mattsson, Ivan Pasic, Abhijat Kitchlu

Summary: Chronic kidney disease (CKD) adversely affects the long-term prognosis for allogeneic hematopoietic stem cell transplant (HSCT) recipients, leading to increased mortality risk and worse graft-versus-host-disease (GVHD)-free/relapse-free survival.

CLINICAL KIDNEY JOURNAL (2022)

Add to Collection

Article Oncology

Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis

Arnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, Myriam Labopin, Martin Bornhaeuser, Matthias Stelljes, Juergen Finke, Arnold Ganser, Herman Einsele, Nicolaus Kroeger, Arne Brecht, Wolfgang Bethge, Matthias Edinger, Aleksandr Kulagin, Jakob Passweg, Igor Wolfgang Blau, Ahmet Elmaagacli, Kerstin Schaefer-Eckart, Uwe Platzbecker, Thomas Schroeder, Donald Bunjes, Johanna Tischer, Sonja Martin, Alexandros Spyridonidis, Sebastian Giebel, Bipin Savani, Mohamad Mohty

Summary: The study evaluated the outcomes of unrelated transplantation for primary refractory/relapsed AML patients, comparing two cohorts from the years 2000-2009 and 2010-2019. The results showed that the outcomes of unrelated transplantation for patients with refractory/relapsed AML have improved in the last two decades, rescuing about one third of the patients.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Biophysics

Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT

Frederic Baron, Myriam Labopin, Didier Blaise, Maija Itala-Remes, Gerard Socie, Edouard Forcade, Ibrahim Yakoub-Agha, Norbert Claude Gorin, Jordi Esteve, Arnon Nagler, Mohamad Mohty

Summary: The indication for performing an allogeneic hematopoietic stem cell transplantation (allo-HCT) in patients with isolated trisomy 8 AML in first complete remission (CR) is still debated. By comparing outcomes of patients given either allo-HCT or autologous (auto)-HCT, it was found that allo-HCT with a HLA-identical sibling donor (MSD) or a 10/10 HLA-matched unrelated donor (UD 10/10) were associated with lower risk of relapse and better leukemia-free survival (LFS) compared to auto-HCT.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection

Article Medicine, General & Internal

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

Silvia Marce, Blanca Xicoy, Olga Garcia, Marta Cabezon, Natalia Estrada, Patricia Velez, Concepcion Boque, Miguel Sagues, Anna Angona, Raul Teruel-Montoya, Francisca Ferrer-Marin, Paula Amat, Juan Carlos Hernandez-Boluda, Mariana M. Ibarra, Eduardo Anguita, Montserrat Cortes, Andres Fernandez-Ruiz, Sandra Fontanals, Lurdes Zamora

Summary: The study found that the expression of e14a2 or e13a2 transcripts in chronic myeloid leukemia (CML) patients does not affect treatment outcomes. Specifically, e14a2 transcripts are associated with better molecular responses in the first 6 months of treatment, while e13a2 is linked to improved long-term overall survival.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Modeling early treatment response in AML from cell-free tumor DNA

Dantong Wang, Christian Rausch, Simon A. Buerger, Sebastian Tschuri, Maja Rothenberg-Thurley, Melanie Schulz, Jan Hasenauer, Frank Ziemann, Klaus H. Metzeler, Carsten Marr

Summary: By studying the kinetics of blast cells and ctDNA in AML patients, we found that ctDNA can be used for less invasive monitoring of AML disease, and a mathematical model can predict bone marrow blast content and relapse risk.

ISCIENCE (2023)

Add to Collection

Article Endocrinology & Metabolism

Incidence and predictors of remission and relapse of type 2 diabetes mellitus in Japan: Analysis of a nationwide patient registry

Kazuya Fujihara, Laymon Khin, Koshiro Murai, Yurie Yamazaki, Kahori Tsuruoka, Noriko Yagyuda, Katsuya Yamazaki, Hiroshi Maegawa, Shiro Tanaka, Satoru Kodama, Hirohito Sone

Summary: This study aimed to determine the incidence of remission and 1-year relapse in patients with type 2 diabetes and associated factors. The overall incidence of remission in Japanese patients was 10.5 per 1000 person-years, with higher rates for those with HbA1c levels of 48 to 53 mmol/mol (6.5% to 6.9%), those taking no glucose-lowering drugs at baseline, and those with a =10% BMI reduction in 1 year. Shorter duration, lower baseline HbA1c, higher baseline BMI, greater BMI reduction at 1 year, and no glucose-lowering drugs at baseline were significantly associated with remission. Among those with remission, approximately two-thirds relapsed within 1 year. Longer duration, lower baseline BMI, and lower BMI reduction at 1 year were significantly associated with relapse.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Hematology

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry

Maja Dam Andersen, Stephen Hamilton-Dutoit, Lena Modvig, Maja Vase, Ilse Christiansen, Jacob Haaber Christensen, Rasmus Bo Dahl-Sorensen, Danny Stoltenberg, Peter Kamper, Francesco d'Amore

Summary: We analysed a large cohort of Hodgkin lymphoma patients to determine the pattern of late recurrence, the influential factors, and the outcome for patients experiencing recurrence.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Letter Hematology

Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT

Michele Wieczorek, Myriam Labopin, Luca Castagna, Eolia Brissot, Gerard Socie, Anna Maria Raiola, Emanuele Angelucci, Arancha Bermudez Rodriguez, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Charles Crawley, Jean Baptiste Mear, Maurizio Musso, Renato Fanin, Daniele Avenoso, Pascal Turlure, Cristina Tecchio, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Sebastian Giebel, Myriam Labopin, Thomas Schroeder, Ryszard Swoboda, Johan Maertens, Jean Henri Bourhis, Giovanni Grillo, Urpu Salmenniemi, Inken Hilgendorf, Nicolaus Kroeger, Xavier Poire, Jan J. Cornelissen, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Arnon Nagler, Mohamad Mohty

Summary: A comparison was made between two myeloablative regimens for acute myeloid leukemia (AML) patients, one involving cyclophosphamide and total body irradiation (CyTBI12Gy) and the other involving fludarabine and total body irradiation (FluTBI12Gy). The results showed that the two regimens had similar efficacy in terms of relapse rate, non-relapse mortality, and survival rate. However, the FluTBI12Gy regimen was associated with a lower incidence of acute graft-versus-host disease and better survival rates.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Editorial Material Hematology

Sequencing anti-BCMA therapies in myeloma

Jean-Luc Harousseau, Mohamad Mohty

BLOOD (2023)

Add to Collection

Article Biophysics

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

Riccardo Saccardi, Hein Putter, Dirk-Jan Eikema, Maria Paula Busto, Eoin McGrath, Bas Middelkoop, Gillian Adams, Marina Atlija, Francis Ayuketang Ayuk, Helen Baldomero, Yves Beguin, Rafael de la Camara, Angel Cedillo, Anna Maria Sureda Balari, Christian Chabannon, Selim Corbacioglu, Harry Dolstra, Rafael F. Duarte, Remy Dulery, Raffaella Greco, Andreu Gusi, Nada Hamad, Michelle Kenyon, Nicolaus Kroeger, Myriam Labopin, Julia Lee, Per Ljungman, Lynn Manson, Florence Mensil, Noel Milpied, Mohamad Mohty, Elena Oldani, Kim Orchard, Jakob Passweg, Rachel Pearce, Regis Peffault de Latour, Helene A. Poirel, Tuula Rintala, J. Douglas Rizzo, Annalisa Ruggeri, Carla Sanchez-Martinez, Fermin Sanchez-Guijo, Isabel Sanchez-Ortega, Marie Trnkova, David Valcarcel Ferreiras, Leonie Wilcox, Liesbeth C. de Wreede, John A. Snowden

Summary: From 2016, EBMT and JACIE developed an international risk-adapted benchmarking program for HSCT outcome. The program aims to assure quality and meet accreditation requirements for EBMT Centers. With input from previous experience, the program established criteria for patient and Center selection and a statistical model based on key clinical variables. The experience so far has shown the feasibility, acceptability, and reliability of the system, while also identifying limitations and future challenges.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Review Biophysics

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT)

Mohamad Mohty, Florent Malard, Ahmed S. Alaskar, Mahmoud Aljurf, Mutlu Arat, Peter Bader, Frederic Baron, Ali Bazarbachi, Didier Blaise, Eolia Brissot, Fabio Ciceri, Selim Corbacioglu, Jean-Hugues Dalle, Fiona Dignan, Anne Huynh, Michelle Kenyon, Arnon Nagler, Antonio Pagliuca, Zinaida Peric, Paul G. Richardson, Annalisa Ruggeri, Tapani Ruutu, Ibrahim Yakoub-Agha, Rafael F. Duarte, Enric Carreras

Summary: Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can occur after hematopoietic cell transplantation (HCT). The European Society for Blood and Marrow Transplantation (EBMT) has recently updated the definition and severity grading system for SOS/VOD in adult patients. The aim of this work is to provide an update on the diagnosis, severity assessment, pathophysiology, and treatment of SOS/VOD in adult patients.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Biophysics

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Gesine Bug, Myriam Labopin, Riitta Niittyvuopio, Matthias Stelljes, Hans Christian Reinhardt, Inken Hilgendorf, Nicolaus Kroeger, Ain Kaare, Wolfgang Bethge, Kerstin Schaefer-Eckart, Mareike Verbeek, Stephan Mielke, Kristina Carlson, Ali Bazarbachi, Alexandros Spyridonidis, Bipin N. Savani, Arnon Nagler, Mohamad Mohty

Summary: Retrospective analysis compared two different conditioning regimens for AML patients undergoing HSCT and found that using FluTBI resulted in lower relapse probability but higher non-relapse mortality. There were no significant differences in overall survival and GRFS between the two groups. Therefore, FluTBI may be more suitable for younger patients below the age of 55.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Biophysics

Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT

Klaus Hirschbuehl, Myriam Labopin, Emmanuelle Polge, Didier Blaise, Jean Henri Bourhis, Gerard Socie, Edouard Forcade, Ibrahim Yakoub-Agha, Helene Labussiere-Wallet, Wolfgang Bethge, Patrice Chevallier, Sarah Bonnet, Matthias Stelljes, Alexandros Spyridonidis, Zinaida Peric, Eolia Brissot, Bipin Savani, Sebastian Giebel, Christoph Schmid, Fabio Ciceri, Arnon Nagler, Mohamad Mohty

Summary: Allogeneic hematopoietic cell transplantation is a curative treatment for high-risk acute lymphoblastic leukemia, and conditioning regimens based on 12 Gray total body irradiation are the standard for patients under 45 years old. However, elderly patients often receive intermediate intensity conditioning to reduce toxicity. A retrospective study compared the outcomes of different conditioning regimens in ALL patients over 45 years old.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Oncology

Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermudez Rodriguez, Peter Remenyi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty

Summary: Comparing outcomes of adult patients with secondary acute myeloid leukemia (sAML) and de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide, no significant difference was observed in transplantation outcomes between the two groups.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Review Immunology

Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia

Mohammad Hassan Hodroj, Iman Abou Dalle, Nour Moukalled, Jean El Cheikh, Mohamad Mohty, Ali Bazarbachi

Summary: The outcome of B-cell acute lymphoblastic leukemia has improved with multi-agent chemotherapy and immunotherapeutic agents. However, relapse post-transplant is still common. This review discusses strategies such as tyrosine kinase inhibitors, innovative agents, and cellular therapy to prevent and overcome relapse post allo-HCT in ALL patients.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Hematology

Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial

Stephan A. Grupp, Selim Corbacioglu, Hyoung Jin Kang, Takanori Teshima, Seong Lin Khaw, Franco Locatelli, Johan Maertens, Matthias Stelljes, Polina Stepensky, Paty Lopez, Vian Amber, Antonio Pagliuca, Paul G. Richardson, Mohamad Mohty

Summary: This study compared defibrotide prophylaxis plus best supportive care to best supportive care alone for preventing sinusoidal obstruction syndrome after hematopoietic stem-cell transplantation. The results showed that defibrotide did not provide a benefit in preventing sinusoidal obstruction syndrome.

LANCET HAEMATOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Acute graft-versus-host disease

Florent Malard, Ernst Holler, Brenda M. Sandmaier, He Huang, Mohamad Mohty

Summary: Acute graft-versus-host disease (GVHD) is a common immune complication that can occur after allogeneic haematopoietic cell transplantation (alloHCT). This Primer summarizes the epidemiology, pathophysiology, diagnosis, prevention and treatment of this disorder. The article also reviews future research avenues and the effect this disorder has on patients' quality of life.

NATURE REVIEWS DISEASE PRIMERS (2023)

Add to Collection

Article Oncology

Global disparities in patients with multiple myeloma: a rapid evidence assessment

Maria-Victoria Mateos, Sikander Ailawadhi, Luciano J. Costa, Shakira J. Grant, Lalit Kumar, Mohamad Mohty, Didem Aydin, Saad Z. Usmani

Summary: This study examined the influence of sociodemographic factors on disparities in outcomes for multiple myeloma patients. The results showed that increasing age and low socioeconomic status were associated with worse patient outcomes globally. In the US, men had worse outcomes while women and minority populations had poorer access to treatment.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Hematology

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Molly C. Tokaz, Helen Baldomero, Andrew J. Cowan, Wael Saber, Hildegard Greinix, Mickey B. C. Koh, Nicolaus Kroeger, Mohamad Mohty, Sebastian Galeano, Shinichiro Okamoto, Naeem Chaudhri, Amado J. Karduss, Fabio Ciceri, Vergilio Antonio R. Colturato, Selim Corbacioglu, Alaa Elhaddad, Lisa M. Force, Cristobal Frutos, Andres Gomez-De Leon, Nada Hamad, Nelson Hamerschlak, Naya He, Aloysius Ho, Xiao-jun Huang, Ben Jacobs, Hee-Je Kim, Minako Iida, Leslie Lehmann, Regis Peffault de Latour, Mary-Elizabeth M. Percival, Martina Perdomo, Walid Rasheed, Kirk R. Schultz, Adriana Seber, Bor-Sheng Ko, Anderson Joao Simione, Alok Srivastava, Jeff Szer, William A. Wood, Yoshihisa Kodera, Arnon Nagler, John A. Snowden, Daniel Weisdorf, Jakob Passweg, Marcelo C. Pasquini, Anna Sureda, Yoshiko Atsuta, Mahmoud Aljurf, Dietger Niederwieser

Summary: Acute myeloid leukemia (AML) is a fast-progressing and historically challenging disease. Hematopoietic stem cell transplantation (HSCT) is the best treatment option for many patients, but access and utilization on a global scale are unclear. This study aimed to investigate the global use of HSCT in AML and identify areas of need. The study found that AML incidence has increased globally, as has the use of HSCT, particularly allogeneic HSCT. However, there are significant regional variations in HSCT utilization and practices, including differences in graft sources. Further research is needed to understand and address these disparities.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection

Article Hematology

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation

Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michele Cavo, Philippe Moreau, Meletios Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie-Laure Risse, Joseph Mikhael

Summary: The role, timing, and impact of transplantation on further therapy after relapse in multiple myeloma (MM) are still being debated in the era of highly active novel agents. The impact of prior transplantation on treatment benefit from monoclonal antibodies in patients with relapsed/refractory MM (RRMM) is largely unknown. This subgroup analysis examined efficacy and safety in patients from the Phase 3 IKEMA study with and without previous transplantation.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection

Article Medicine, Research & Experimental

Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

Vincent Jachiet, Laure Ricard, Pierre Hirsch, Florent Malard, Laurent Pascal, Odile Beyne-Rauzy, Pierre Peterlin, Alexandre Thibault Jacques Maria, Norbert Vey, Maud D'Aveni, Marie-Pierre Gourin, Sophie Dimicoli-Salazar, Anne Banos, Stefan Wickenhauser, Louis Terriou, Benoit De Renzis, Eric Durot, Shanti Natarajan-Ame, Anne Vekhoff, Laurent Voillat, Sophie Park, Julien Vinit, Celine Dieval, Azeddine Dellal, Vincent Grobost, Lise Willems, Julien Rossignol, Eric Solary, Olivier Kosmider, Nicolas Dulphy, Lin Pierre Zhao, Lionel Ades, Pierre Fenaux, Olivier Fain, Mohamad Mohty, Beatrice Gaugler, Arsene Mekinian

Summary: Background systemic inflammatory and autoimmune diseases (SIADs) occur in a significant proportion of myelodysplastic syndrome (MDS) patients. The recently identified VEXAS syndrome, associated with somatic mutations in UBA1, is characterized by severe inflammatory conditions and hematological abnormalities, including MDS. However, the mechanisms underlying the association between MDS and SIADs are largely unknown. This study aimed to evaluate myeloid immune cell subsets in MDS patients with and without SIAD and compare them to healthy controls.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.